These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 24849787)

  • 21. Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression.
    Fu R; Jiang S; Li J; Chen H; Zhang X
    Med Oncol; 2020 Mar; 37(4):24. PubMed ID: 32166604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
    Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
    Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-c-MET Nanobody - a new potential drug in multiple myeloma treatment.
    Slørdahl TS; Denayer T; Moen SH; Standal T; Børset M; Ververken C; Rø TB
    Eur J Haematol; 2013 Nov; 91(5):399-410. PubMed ID: 23952536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anticancer molecular mechanisms of oleocanthal.
    El Haouari M; Quintero JE; Rosado JA
    Phytother Res; 2020 Nov; 34(11):2820-2834. PubMed ID: 32449241
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oleocanthal inhibits proliferation and MIP-1α expression in human multiple myeloma cells.
    Scotece M; Gómez R; Conde J; Lopez V; Gómez-Reino JJ; Lago F; Smith AB; Gualillo O
    Curr Med Chem; 2013; 20(19):2467-75. PubMed ID: 23521677
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.
    Lal B; Goodwin CR; Sang Y; Foss CA; Cornet K; Muzamil S; Pomper MG; Kim J; Laterra J
    Mol Cancer Ther; 2009 Jul; 8(7):1751-60. PubMed ID: 19584231
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibitory action of naphtho[1,2-b]furan-4,5-dione on hepatocyte growth factor-induced migration and invasion of MDA-MB-231 cells: mechanisms of action.
    Tsai PC; Chu CL; Tseng CH; Chen YL; Chang LS; Lin SR
    Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):716-26. PubMed ID: 24909202
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PTEN reconstitution alters glioma responses to c-Met pathway inhibition.
    Goodwin CR; Lal B; Ho S; Woodard CL; Zhou X; Taeger A; Xia S; Laterra J
    Anticancer Drugs; 2011 Oct; 22(9):905-12. PubMed ID: 21654317
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HGF-induced PKCζ activation increases functional CXCR4 expression in human breast cancer cells.
    Huang S; Ouyang N; Lin L; Chen L; Wu W; Su F; Yao Y; Yao H
    PLoS One; 2012; 7(1):e29124. PubMed ID: 22242160
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy.
    Li Y; Lal B; Kwon S; Fan X; Saldanha U; Reznik TE; Kuchner EB; Eberhart C; Laterra J; Abounader R
    Cancer Res; 2005 Oct; 65(20):9355-62. PubMed ID: 16230398
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiotoxin III Inhibits Hepatocyte Growth Factor-Induced Epithelial-Mesenchymal Transition and Suppresses Invasion of MDA-MB-231 Cells.
    Tsai PC; Fu YS; Chang LS; Lin SR
    J Biochem Mol Toxicol; 2016 Jan; 30(1):12-21. PubMed ID: 26277884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
    Ma JG; Huang H; Chen SM; Chen Y; Xin XL; Lin LP; Ding J; Liu H; Meng LH
    Breast Cancer Res Treat; 2011 Nov; 130(1):85-96. PubMed ID: 21181437
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer.
    De Bacco F; Luraghi P; Medico E; Reato G; Girolami F; Perera T; Gabriele P; Comoglio PM; Boccaccio C
    J Natl Cancer Inst; 2011 Apr; 103(8):645-61. PubMed ID: 21464397
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.
    Christensen JG; Schreck R; Burrows J; Kuruganti P; Chan E; Le P; Chen J; Wang X; Ruslim L; Blake R; Lipson KE; Ramphal J; Do S; Cui JJ; Cherrington JM; Mendel DB
    Cancer Res; 2003 Nov; 63(21):7345-55. PubMed ID: 14612533
    [TBL] [Abstract][Full Text] [Related]  

  • 35. EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors.
    Bladt F; Faden B; Friese-Hamim M; Knuehl C; Wilm C; Fittschen C; Grädler U; Meyring M; Dorsch D; Jaehrling F; Pehl U; Stieber F; Schadt O; Blaukat A
    Clin Cancer Res; 2013 Jun; 19(11):2941-51. PubMed ID: 23553846
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SU5416 is a potent inhibitor of hepatocyte growth factor receptor (c-Met) and blocks HGF-induced invasiveness of human HepG2 hepatoma cells.
    Wang SY; Chen B; Zhan YQ; Xu WX; Li CY; Yang RF; Zheng H; Yue PB; Larsen SH; Sun HB; Yang X
    J Hepatol; 2004 Aug; 41(2):267-73. PubMed ID: 15288476
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The orally bioavailable met inhibitor PF-2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model.
    Sampson ER; Martin BA; Morris AE; Xie C; Schwarz EM; O'Keefe RJ; Rosier RN
    J Bone Miner Res; 2011 Jun; 26(6):1283-94. PubMed ID: 21308771
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transforming growth factor-beta signaling-deficient fibroblasts enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasion.
    Cheng N; Chytil A; Shyr Y; Joly A; Moses HL
    Mol Cancer Res; 2008 Oct; 6(10):1521-33. PubMed ID: 18922968
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overexpression of ING5 inhibits HGF-induced proliferation, invasion and EMT in thyroid cancer cells via regulation of the c-Met/PI3K/Akt signaling pathway.
    Gao W; Han J
    Biomed Pharmacother; 2018 Feb; 98():265-270. PubMed ID: 29272787
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis.
    Zillhardt M; Park SM; Romero IL; Sawada K; Montag A; Krausz T; Yamada SD; Peter ME; Lengyel E
    Clin Cancer Res; 2011 Jun; 17(12):4042-51. PubMed ID: 21551255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.